Carrick Therapeutics announced a $35M investment from Pfizer to support its rapid development of samuraciclib in HR+, HER2- breast cancer, which represents more than two thirds of all new female breast cancer cases.1 Carrick and Pfizer have also entered into an agreement under which Pfizer will provide global development capabilities and expertise to support Carrick’s Phase 2 study of samuraciclib in combination with fulvestrant for CDK4/6i-resistant HR+, HER2- advanced breast cancer. Carrick will maintain full economic ownership and control of samuraciclib and its pipeline. In conjunction with the investment, Adam Schayowitz, Ph.D., Vice President and Development Head, Breast Cancer, Colorectal Cancer and Melanoma, Pfizer Global Product Development, will join Carrick’s Scientific Advisory Board.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer call volume above normal and directionally bullish
- Top Viatris (NASDAQ:VTRS) Executive Charged With Insider Trading
- Meet Silo Pharma: Fly exclusive interview with CEO Weisblum, VP of R&D Kuo
- #SocialStocks: Shares responds as Meta axes 13% of workforce
- PFE, JNJ, or CVS: Which Healthcare Stock is a “Strong Buy” for Wall Street Pros?
